Results 141 to 150 of about 7,919 (172)

Macrophage-Derived CCL24 Promotes Cardiac Fibrosis Via Fibroblast CCR3. [PDF]

Circ Res
Parthiban P, Barrow F, Wang H, Chalise U, Araujo N, Souza-Neto F, Nguyen H, Draxler M, Pallais JP, Yucel D, Liu H, Ciske E, Fehrenbach P, Hakeem A, Lee SH, Herman A, Rothenberg ME, Dudley S, van Berlo JH, Revelo XS.   +19 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Small molecule antagonists for chemokine CCR3 receptors

Medicinal Research Reviews, 2010
AbstractThe chemokine receptor CCR3 is believed to play a role in the development of allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis. Despite the conflicting results that have been reported regarding the importance of eosinophils and CCR3 in allergic inflammation, inhibition of this receptor with small molecule antagonists is
Lianne I Willems, Adriaan P Ijzerman
exaly   +4 more sources

Expression of the Chemokine Receptor CCR3 on Human Mast Cells

International Archives of Allergy and Immunology, 2001
<i>Background:</i> The aim of this study was to investigate whether human mast cells express functional active CCR3 receptors, which are activated by CC chemokines. These ligands include the CCR3-selective chemokines eotaxin and eotaxin-2 and the more promiscuous CC chemokines, MCP-4, MCP-3, MCP-2 and RANTES.
A. DE PAOLIS, ANNUNZIATO, FRANCESCO, L. DI GIOIA, ROMAGNANI, SERGIO, M. CANFORA, C. BELTRAME, G. MARONE, ROMAGNANI, PAOLA   +7 more
openaire   +4 more sources

A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor

European Journal of Pharmacology, 2007
Eosinophilic chemokines and histamine play distinct but important roles in allergic diseases. Inhibition of both eosinophilic chemokines and histamine, therefore, is an ideal strategy for the treatment of allergic inflammation, such as asthma, allergic rhinitis, and atopic dermatitis.
Keiko, Suzuki, Tatsuaki, Morokata, Koichiro, Morihira, Ippei, Sato, Satoko, Takizawa, Masayuki, Kaneko, Koichiro, Takahashi, Yasuaki, Shimizu   +7 more
openaire   +2 more sources

Eotaxin Receptor (CCR3) Antagonism in Asthma and Allergic Disease

Current Drug Target -Inflammation & Allergy, 2002
A range of low molecular weight chemicals have been developed to antagonise the eotaxin receptor, cysteine-cysteine chemokine receptor-3 (CCR3), with the aim of selectively inhibiting eosinophil recruitment into tissue sites. However, the results of recent clinical trials with monoclonal antibodies directed against interleukin-5 (IL-5) question the ...
E M, Erin, T J, Williams, P J, Barnes, T T, Hansel   +3 more
openaire   +2 more sources

CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia

Nature, 1997
Several members of the chemokine receptor family are used together with CD4 for HIV-1 entry into target cells. T cell line-tropic (T-tropic) HIV-1 viruses use the chemokine receptor CXCR4 as a co-receptor, whereas macrophage-tropic (M-tropic) primary viruses use CCR5 (refs 2-6).
J, He, Y, Chen, M, Farzan, H, Choe, A, Ohagen, S, Gartner, J, Busciglio, X, Yang, W, Hofmann, W, Newman, C R, Mackay, J, Sodroski, D, Gabuzda   +12 more
openaire   +2 more sources

Eotaxins and CCR3 Receptor in Inflammatory and Allergic Skin Diseases: Therapeutical Implications

Current Drug Target -Inflammation & Allergy, 2003
Cell migration is mediated by a group of chemotactic cytokines called chemokines: low molecular weight molecules that have been shown as important leukocyte chemical attractants to sites of inflammation and infection. Eotaxin-1, also called CCL11, was first described in 1994, as a highly specific eosinophils chemokine.
AMERIO, Paolo, FREZZOLINI A, FELICIANI, Claudio, VERDOLINI R, TEOFOLI P, DE PITA O, PUDDU P.   +6 more
openaire   +3 more sources

Discovery of CC Chemokine Receptor-3 (CCR3) Antagonists with Picomolar Potency

Journal of Medicinal Chemistry, 2005
Starting with our previously described(20) class of CC chemokine receptor-3 (CCR3) antagonist, we improved the potency by replacing the phenyl linker of 1 with a cyclohexyl linker and by replacing the 4-benzylpiperidine with a 3-benzylpiperidine. The resulting compound, 32, is a potent and selective antagonist of CCR3.
George V, De Lucca, Ui Tae, Kim, Brian J, Vargo, John V, Duncia, Joseph B, Santella, Daniel S, Gardner, Changsheng, Zheng, Ann, Liauw, Zhang, Wang, George, Emmett, Dean A, Wacker, Patricia K, Welch, Maryanne, Covington, Nicole C, Stowell, Eric A, Wadman, Anuk M, Das, Paul, Davies, Swamy, Yeleswaram, Danielle M, Graden, Kimberly A, Solomon, Robert C, Newton, George L, Trainor, Carl P, Decicco, Soo S, Ko   +23 more
openaire   +2 more sources

Novel Ligands for the Chemokine Receptor-3 (CCR3):  A Receptor-Modeling Study Based on 5D-QSAR

Journal of Medicinal Chemistry, 2005
We recently reported the development of a receptor-modeling concept based on 5D-QSAR (quantitative structure-activity relationships) and which explicitly allows for the simulation of induced fit. In this account, we report its utilization toward the design of novel compounds able to inhibit the chemokine receptor-3 (CCR3).
Angelo, Vedani, Max, Dobler, Horst, Dollinger, Kai-Malte, Hasselbach, Franz, Birke, Markus A, Lill   +5 more
openaire   +2 more sources